Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2003 March;55(1) > Minerva Urologica e Nefrologica 2003 March;55(1):91-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

REVIEWS  


Minerva Urologica e Nefrologica 2003 March;55(1):91-9

language: English

Mycophenolate mofetil in pediatric renal transplantation

Weber L. T., Höcker B., Mehls O., Tönshoff B.

Division of Pediatric Nephrology, University Children’s Hospital, Heidelberg, Germany


Full text temporarily not available online. Contact us  


Since my­co­phen­o­late mofe­til (MMF), an es­ter pro­drug of the im­mu­no­sup­press­ant my­coph­e­nol­ic ac­id (MPA), has ­been ap­proved for main­te­nance im­mu­no­sup­pres­sive ther­a­py al­so in chil­dren af­ter re­nal trans­plan­ta­tion it has be­come an im­por­tant ­part of im­mu­no­sup­pres­sive pro­to­cols. By in­hib­it­ing in­osine mono­phos­phate de­hy­drog­e­nase, the key en­zyme in the de no­vo pu­rine bi­o­syn­the­sis of pro­life­rat­ing T and B lym­pho­cytes, MMF ­acts as a rel­a­tive­ly spe­cif­ic in­hib­i­tor of hu­man lym­pho­cyte pro­life­ra­tion. MMF is ­more ef­fec­tive ­than az­a­thi­o­prine in com­bi­na­tion ­with cy­clo­spor­in A (CsA) and cor­ti­cos­ter­oids and dis­tinct­ly re­duc­es the in­ci­dence of ­acute re­jec­tion epi­sodes in the ­1st ­year ­post-trans­plant in ­adults as ­well as in chil­dren. Beneficial ef­fects on ster­oid-re­sist­ant re­jec­tion and chron­ic al­lo­graft dys­func­tion ­have ­been ­shown. In gen­er­al, MMF is ­well tol­er­at­ed. Major ad­verse ­events in pe­di­at­ric re­nal trans­plant re­cip­ients in­clude leu­ko­pe­nia, in­fec­tions and gas­troin­tes­ti­nal prob­lems. Pharmacokinetic mon­i­tor­ing of MPA can ­help to op­tim­ise MMF ther­a­py af­ter re­nal trans­plan­ta­tion, as as­so­ci­a­tions ­between the ­risk of ­acute re­jec­tion epi­sodes and MPA-AUC val­ues and MPA pre­dose lev­els ­have ­been dem­on­strat­ed. The in­ci­dence of MMF-re­lat­ed ­side ef­fects ­such as leu­ko­pe­nia and/or in­fec­tions, how­ev­er, is as­so­ciat­ed ­with phar­ma­cok­i­net­ic pa­ram­e­ters of ­free MPA. Reference ­data of rel­e­vant phar­ma­cok­i­net­ic pa­ram­e­ters are avail­able. The pos­sible ster­oid-spar­ing po­ten­tial of MMF is an im­por­tant is­sue in pe­di­at­ric re­nal trans­plan­ta­tion. Preliminary ­data dem­on­strate im­proved lon­gi­tu­di­nal ­growth, ­less cu­shin­goid hab­it­us and low­er ­blood pres­sure af­ter ster­oid-with­draw­al in pe­di­at­ric re­nal trans­plant re­cip­ients ­under MMF and CsA ther­a­py.

top of page

Publication History

Cite this article as

Corresponding author e-mail